- Home
- MED vs CHRS Comparison
MED vs CHRS Comparison
Compare MED & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- CHRS
- Stock Information
- Founded
- MED 1980
- CHRS 2010
- Country
- MED United States
- CHRS United States
- Employees
- MED N/A
- CHRS 235
- Industry
- MED Packaged Foods
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MED Consumer Staples
- CHRS Health Care
- Exchange
- MED Nasdaq
- CHRS Nasdaq
- Market Cap
- MED 187.3M
- CHRS 134.4M
- IPO Year
- MED N/A
- CHRS 2014
- Fundamental
- Price
- MED $15.41
- CHRS $1.22
- Analyst Decision
- MED Hold
- CHRS Strong Buy
- Analyst Count
- MED 1
- CHRS 4
- Target Price
- MED $17.00
- CHRS $5.38
- AVG Volume (30 Days)
- MED 204.6K
- CHRS 2.4M
- Earning Date
- MED 02-18-2025
- CHRS 03-12-2025
- Dividend Yield
- MED N/A
- CHRS N/A
- EPS Growth
- MED N/A
- CHRS N/A
- EPS
- MED 0.67
- CHRS N/A
- Revenue
- MED $674,475,000.00
- CHRS $304,340,000.00
- Revenue This Year
- MED N/A
- CHRS $2.47
- Revenue Next Year
- MED N/A
- CHRS N/A
- P/E Ratio
- MED $23.25
- CHRS N/A
- Revenue Growth
- MED N/A
- CHRS 44.19
- 52 Week Low
- MED $14.88
- CHRS $0.66
- 52 Week High
- MED $56.52
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- MED 36.38
- CHRS 44.03
- Support Level
- MED $15.67
- CHRS $1.03
- Resistance Level
- MED $16.30
- CHRS $1.23
- Average True Range (ATR)
- MED 0.55
- CHRS 0.13
- MACD
- MED 0.09
- CHRS -0.02
- Stochastic Oscillator
- MED 25.16
- CHRS 38.89
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.